Searchable abstracts of presentations at key conferences in endocrinology

ea0063p200 | Diabetes, Obesity and Metabolism 1 | ECE2019

PCSK9 inhibitors effects after 2 years in real life

Gonzalez Molero Inmaculada , Marin Montserrat Gonzalo , Gamgaram Viyey Kishore Doulatram , Fernandez Jose Abuin , Garcia Ignacio Ruiz , Herrera Maria Jose Vallejo , Fuster Gabriel Olveira

Introduction: Recently, PCSK9 inhibitors have been approved in our country for familial hypercholesterolemia and for patients with cardiovascular diseases. They are still scarce data in real life patients effects.Objective: Analyse the features of first patients treated with PCSK9 inhibitors in a specific unit of familial dyslipidemia and the effect on lipid profile and other clinical variables.Material and methods: Data from patie...